ADVERTISEMENT

Stock Picks Today: Adani Ports, Bharti Airtel, Britannia, Gland Pharma On Brokerages' Radar

Adani Ports and Special Economic Zone Ltd., Bharti Airtel Ltd., Britannia Ltd., Gland Pharma Ltd., and Aegis Vopak are among the companies garnering brokerage commentary today.

<div class="paragraphs"><p>Adani Ports and Special Economic Zone Ltd., Bharti Airtel Ltd., Britannia Ltd., Gland Pharma Ltd., and Aegis Vopak are among the companies garnering brokerage commentary today (Image source: Envato)</p></div>
Adani Ports and Special Economic Zone Ltd., Bharti Airtel Ltd., Britannia Ltd., Gland Pharma Ltd., and Aegis Vopak are among the companies garnering brokerage commentary today (Image source: Envato)

Adani Ports and Special Economic Zone Ltd., Bharti Airtel Ltd., Britannia Ltd., Gland Pharma Ltd., and Aegis Vopak are among the companies garnering brokerage commentary today.

Analysts have shared their insights and, in several cases, revised their target prices based on their updated fundamental outlooks for these firms, broadly based on the first quarter financials that the players have put out. Here are the key analyst calls to watch out for today:

Jefferies on Aegis Vopak

  • Initiate Hold with target price of Rs 270

  • Play on India’s Liquified Petroleum Gas (LPG) consumption growth, led by imports

  • Company owns and operates a network of storage terminals for LPG and Liquid products

  • Expect 28% FY25-30E Ebitda CAGR led by organic/inorganic capacity expansions

  • See improved asset utilization through evacuation infrastructure buildout

  • Stock is trading at 34x 12M forward EV/Ebitda, limiting upside

On Bharti Airtel

Macquarie

  • Maintain Outperform with target price of Rs 2050

  • Strong ARPU gain, capex control, record free cash flow

  • Strong print in India mobile with ARPU and FCF tracking above forecasts

  • Record FCF generation in particular will likely drive positive sentiment as the Street was mixed on capex trajectory and FCF delivery

Citi

  • Maintain Buy with target price of Rs 2250

  • Q1: Steady quarter + Lower Capex Drives Solid free cash flow + Deleveraging

  • Homes segment delivered strong sequential growth led by robust sub adds

  • We are encouraged by the Q1 performance

Morgan Stanley

  • Maintain Equal-weight with target price of Rs 1890

  • Q1: Slight beat on India Ebitda

  • Consol net debt decreased partly because of reduction in capex and higher cash flow generation than expected

  • India mobile business ARPU trending in right direction at Rs 250; share of postpaid went up to 7.3%

On Adani Ports

Jefferies

  • Maintain Buy; Hike target price to Rs 1815 from Rs 1765

  • New port additions drive volume growth

  • Q1 Ebitda was 14% above estimates, led by domestic ports margin improvement and YoY revenue rise in Logistics and Marine

  • Mgmt. reiterated focus on absolute EBITDA growth

  • Company intends to deliver end-to-end solutions vs. pure volume driven growth

  • FY26 volume guidance at 505-515 MT (12-14% YoY) was maintained

Bernstein

  • Maintain Outperform with target price of Rs 1617

  • Revenue showed sharp growth; EBITDA beat by 10%

  • Growth driven by new businesses and ports, with core ports EBITDA near flat

  • See strong pricing power and opportunities to expand into logistics

Goldman Sachs

  • Maintain Buy; Hike target price to Rs 1510 from Rs 1480

  • Resilient port operations; Strong growth in logistics

  • Strong portfolio of port assets leverages it for market share gains

  • As Balance Sheet gets stronger, it positions Adani Port for more organic and inorganic growth opportunities

  • After the recent correction risk-reward looks more attractive

On Britannia

Macquarie

  • Maintain Underperform with target price of Rs 4850

  • Q1 Ebitda miss on weaker gross margin

  • Believe underlying 1Q volume growth was ~4%

  • Company’s comment pointing to a heightened competitive landscape across product categories

  • Focused on sustaining a healthy growth trajectory while protecting margins

Morgan Stanley

  • Maintain Equal-weight with target price of Rs 5511

  • Q1: Margin miss led by higher competitive intensity

  • Both Urban and Rural saw a marginal uptick in consumption

  • Expects to sustain growth with continued brand investments and product innovation

On Gland Pharma

Citi

  • Maintain Sell with target price of Rs 1680

  • Q1: Improvement in Cenexy Offsets Subdued Base-Line Business

  • Management was upbeat on Cenexy outlook

  • Commentary around GLP-1 Pen/Cartridge pickup may moderate Street expectations

Jefferies

  • Upgrade to Hold from Underperform; Hike TP to Rs 1950 from Rs 1350

  • Revenue miss but Cenexi breakeven leads to in-line Ebitda

  • Ebitda margin improves as Cenexi breaks even

  • US growth below par but guidance strong for the year

  • GLP helps to drive strong growth in core markets

  • Europe growth supported by new launches

  • Worst Behind but Valuations Leave Limited Upside

Opinion
Q1 Results Updates: Lupin Profit Spikes, Beats Estimates; Britannia, Gujarat Gas Profit Miss Estimates
OUR NEWSLETTERS
By signing up you agree to the Terms & Conditions of NDTV Profit